Data Sheet (Cat.No.T10567)

TargetMol

BMS-214662

Chemical Properties



CAS No. : 195987-41-8

Formula: C25H23N5O2S2

Molecular Weight: 489.61

Storage: Store at low temperature
Pure form: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	BMS-214662 is a selective farnesyl transferase inhibitor with antitumor activity, useful in studies of pancreatic, head and neck, and lung cancers.
Targets(IC50)	Transferase,Ras
In vitro	BMS-214662 is a potent selective farnesyl transferase (FTI) inhibitor with antitumor activity. [2] BMS-214662 (250 nM, 24h) induces mitochondrial apoptosis in chronic myelogenous leukemia (CmL) stem/progenitor cells, including CD34+38- cells, by activating protein kinase Cbeta. [1]
In vivo	HCT-116 xenograft mice, BMS-214662 (250 mg/kg intravenously,300 mg/kg or 400 mg/kg orally), induced tumor cell apoptosis. For HCT-116 and EJ-1 tumors, the doses of BMS-214662 required to kill 90% of cloned tumor-forming cells were approximately 75 and 100 mg/kg, respectively. [3]

Solubility Information

Solubility	H2O: < 1 mg/mL (insoluble) DMSO: 80 mg/mL (163.4 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (6.74 mM),Sonication is recommended. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.0424 mL	10.2122 mL	20.4244 mL
5 mM	0.4085 mL	2.0424 mL	4.0849 mL
10 mM	0.2042 mL	1.0212 mL	2.0424 mL
50 mM	0.0408 mL	0.2042 mL	0.4085 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Pellicano F, et al. BMS-214662 induces mitochondrial apoptosis in chronic myeloid leukemia (CmL) stem/progenitor cells, including CD34+38- cells, through activation of protein kinase Cbeta. Blood. 2009 Nov 5;114 (19):4186-96.

Rose WC, et al. Preclinical antitumor activity of BMS-214662, a highly apoptotic and novel farnesyltransferase inhibitor. Cancer Res. 2001 Oct 15;61(20):7507-17.

Gómez-Benito M, et al. Farnesyltransferase inhibitor BMS-214662 induces apoptosis in myeloma cells through PUMA up-regulation, Bax and Bak activation, and Mcl-1 elimination. Mol Pharmacol. 2005 Jun;67(6):1991-8.

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481